Myriad Genetics Other Current Liabilities

Myriad Genetics (MYGN) currently reports a other current liabilities of $93M as of June 2026. That compares with $96M in the prior-year period — down 2.6% year over year. Use the charts on this page to explore Myriad Genetics's other current liabilities history and peer comparisons.

Myriad Genetics's other current liabilities decreased from $96M to $93M — a 2.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Myriad Genetics reported $93M in other current liabilities as of June 2026. That compares with $96M in the prior-year period — down 2.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $93M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Myriad Genetics, and consider following MYGN for alerts when major investors trade the stock.

Myriad Genetics is classified in the Healthcare sector. On other current liabilities, it currently shows $93M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MYGN with unrelated industries.